- €476.90m
- €428.10m
- $297.20m
- 74
- 24
- 70
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 85.17 | ||
| PEG Ratio (f) | 0.93 | ||
| EPS Growth (f) | 1,156.84% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.46 | ||
| Price to Tang. Book | 3.39 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.83 | ||
| EV to EBITDA | 127.13 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.64% | ||
| Return on Equity | -5.38% | ||
| Operating Margin | -2.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 212.17 | 198.87 | 205.62 | 245.32 | 297.2 | 325.08 | 357.06 | 9.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -6.61 | -31.14 | -75.86 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
Directors
- Paul Sekhri NEC (63)
- Sijmen de Vries CEO (61)
- Deborah Jorn NVC (63)
- Jeroen Wakkerman CFO (52)
- Mireille Sanders COO (52)
- Robert Friesen CSO
- Anne-Marie de Groot CCO (39)
- Stephen Toor GMG (49)
- Anurag Relan OTH
- Aad de Winter NID (68)
- Mark Pykett NID (57)
- Jonh Ward NID (82)
- Barbara Yanni NID (67)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 11th, 1988
- Public Since
- July 2nd, 1998
- No. of Employees
- 426
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Euronext - Amsterdam- Shares in Issue
- 680,308,735
- Address
- Darwinweg 24, LEIDEN, 2333 CR
- Web
- https://www.pharming.com/
- Phone
- +31 715247400
- Auditors
- Deloitte Accountants B.V.
Latest News for PHARM
Upcoming Events for PHARM
Q1 2025 Pharming Group NV Earnings Release
Pharming Group NV Annual Shareholders Meeting
Q2 2025 Pharming Group NV Earnings Release
FAQ
As of Today at 22:37 UTC, shares in Pharming NV are trading at €0.70. This share price information is delayed by 15 minutes.
Shares in Pharming NV last closed at €0.70 and the price had moved by -27.02% over the past 365 days. In terms of relative price strength the Pharming NV share price has underperformed the FTSE Global All Cap Index by -28.3% over the past year.
The overall consensus recommendation for Pharming NV is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePharming NV does not currently pay a dividend.
Pharming NV does not currently pay a dividend.
Pharming NV does not currently pay a dividend.
To buy shares in Pharming NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of €0.70, shares in Pharming NV had a market capitalisation of €476.90m.
Here are the trading details for Pharming NV:
- Country of listing: Netherlands
- Exchange: AEX
- Ticker Symbol: PHARM
Based on an overall assessment of its quality, value and momentum Pharming NV is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Pharming NV is €5.81. That is 728.53% above the last closing price of €0.70.
Analysts covering Pharming NV currently have a consensus Earnings Per Share (EPS) forecast of $0.02 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pharming NV. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -11.39%.
As of the last closing price of €0.70, shares in Pharming NV were trading -10.41% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pharming NV PE ratio based on its reported earnings over the past 12 months is 85.17. The shares last closed at €0.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pharming NV's management team is headed by:
- Paul Sekhri - NEC
- Sijmen de Vries - CEO
- Deborah Jorn - NVC
- Jeroen Wakkerman - CFO
- Mireille Sanders - COO
- Robert Friesen - CSO
- Anne-Marie de Groot - CCO
- Stephen Toor - GMG
- Anurag Relan - OTH
- Aad de Winter - NID
- Mark Pykett - NID
- Jonh Ward - NID
- Barbara Yanni - NID